Beijing Tiantan Biological Products Corporation LimitedSSE: 600161

Announcement on the Receipt of Clinical Trial Summary Report by a Subsidiary

· Issued by Beijing Tiantan Biological Products Corporation Limited via Shanghai Stock Exchange

Filed with SSE · · 2 pages · Chinese

Summary by 6ix AI

Beijing Tiantan Biological Products Corporation Limited announced that its subsidiary has received a clinical trial summary report for a new product. The product, developed by Guizhou Biopharmaceutical Co., significantly improves coagulation factors in patients with hemophilia B and shows good safety results. This announcement does not significantly impact the company's recent performance, and investors are advised to be aware of potential risks.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Release

Announcement on the Receipt of Clinical Trial Summary Report by a Subsidiary

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Beijing Tiantan Biological Products Corporation Limited on 6ix

Earlier from Beijing Tiantan Biological Products

Later from Beijing Tiantan Biological Products

All Beijing Tiantan Biological Products news releases